IN8BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
IN8BIO, INC. (INAB) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $3.19 per share as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $3.19.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $5.26.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $18.60.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $16.63.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $3.19 10-Q · filed 2026-08-06 |
| 2026-03-31 | $5.26 10-Q · filed 2026-05-07 |
| 2025-12-31 | $18.60 10-K · filed 2026-03-12 |
| 2025-09-30 | $16.63 10-Q · filed 2025-11-06 |
| 2025-06-30 | $17.65 10-Q · filed 2025-08-07 |
| 2025-03-31 | $0.67 10-Q · filed 2025-05-07 |
| 2024-12-31 | $0.91 10-K · filed 2025-03-13 |
| 2024-09-30 | $1.35 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.92 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.05 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.54 10-K · filed 2024-03-14 |
| 2023-09-30 | $2.63 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.75 10-Q · filed 2023-08-10 |
| 2023-03-31 | $4.45 10-Q · filed 2023-05-12 |
| 2022-12-31 | $4.41 10-K · filed 2023-03-30 |
| 2022-09-30 | $5.41 10-Q · filed 2022-11-10 |
| 2022-06-30 | $5.51 10-Q · filed 2022-08-12 |
| 2022-03-31 | $5.98 10-Q · filed 2022-05-12 |
| 2021-12-31 | $6.83 10-K · filed 2022-03-17 |
| 2021-09-30 | $6.87 10-Q · filed 2021-11-10 |
| 2021-06-30 | $5.64 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |